NCCN Categories of Evidence and Consensus
Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
All recommendations are category 2A unless otherwise noted.
Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Akhtar S, Oza KK, Wright J. Merkel cell carcinoma: report of 10 cases and review of the literature. J Am Acad Dermatol 2000;43:755–767.
Gillenwater AM, Hessel AC, Morrison WH et al.. Merkel cell carcinoma of the head and neck: effect of surgical excision and radiation on recurrence and survival. Arch Otolaryngol Head Neck Surg 2001;127:149–154.
Medina-Franco H, Urist MM, Fiveash J et al.. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol 2001;8:204–208.
Allen PJ, Bowne WB, Jaques DP et al.. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 2005;23:2300–2309.
Bichakjian CK, Lowe L, Lao CD et al.. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer 2007;110:1–12.
Lemos BD, Storer BE, Iyer JG et al.. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 2010;63:751–761.
Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;319:1096–1100.
Rollison DE, Giuliano AR, Becker JC. New virus associated with merkel cell carcinoma development. J Natl Compr Canc Netw 2010;8:874–880.
Amber K, McLeod MP, Nouri K. The Merkel cell polyomavirus and its involvement in Merkel cell carcinoma. Dermatol Surg 2013;39:232–238.
Miller SJ, Alam M, Andersen J et al.. NCCN Clinical Practice Guidelines in Oncology for Merkel Cell Carcinoma. J Natl Compr Canc Netw 2006;4:704–712.
Rao P, Balzer BL, Lemos BD et al.. Protocol for the examination of specimens from patients with merkel cell carcinoma of the skin. Arch Pathol Lab Med 2010;134:341–344.
Fields RC, Busam KJ, Chou JF et al.. Recurrence and survival in patients undergoing sentinel lymph node biopsy for Merkel cell carcinoma: analysis of 153 patients from a single institution. Ann Surg Oncol 2011;18:2529–2537.
Schwartz JL, Griffith KA, Lowe L et al.. Features predicting sentinel lymph node positivity in Merkel cell carcinoma. J Clin Oncol 2011;29:1036–1041.
Paulson KG, Iyer JG, Tegeder AR et al.. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011;29:1539–1546.
Fields RC, Busam KJ, Chou JF et al.. Five hundred patients with merkel cell carcinoma evaluated at a single institution. Ann Surg 2011;254:465–475.
Cheuk W, Kwan MY, Suster S, Chan JK. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med 2001;125:228–231.
- Search Google Scholar
- Export Citation
. Cheuk W Kwan MY Suster S Chan JK Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med 2001; 125: 228– 231.
Hanly AJ, Elgart GW, Jorda M et al.. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates merkel cell carcinoma from small cell carcinoma of lung. J Cutan Pathol 2000;27:118–120.
Gruber SB, Wilson LD. Merkel cell carcinoma. In: Miller SJ, Maloney ME, eds.: Cutaneous Oncology: Pathophysiology, Diagnosis, and Management. Malden, MA: Blackwell Science; 1998:710–721.
Siva S, Byrne K, Seel M et al.. 18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience. J Nucl Med 2013;54:1223–1229.
Hawryluk EB, O’Regan KN, Sheehy N et al.. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women’s Cancer Center. J Am Acad Dermatol 2013;68:592–599.
Treglia G, Kakhki VR, Giovanella L, Sadeghi R. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with Merkel cell carcinoma: a systematic review and meta-analysis. Am J Clin Dermatol 2013;14:437–447.
Kokoska ER, Kokoska MS, Collins BT et al.. Early aggressive treatment for Merkel cell carcinoma improves outcome. Am J Surg 1997;174:688–693.
Ott MJ, Tanabe KK, Gadd MA et al.. Multimodality management of Merkel cell carcinoma. Arch Surg 1999;134:388–392; discussion 392-393.
Pitale M, Sessions RB, Husain S. An analysis of prognostic factors in cutaneous neuroendocrine carcinoma. Laryngoscope 1992;102:244–249.
Skelton HG, Smith KJ, Hitchcock CL et al.. Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol 1997;37:734–739.
Schneider S, Thurnher D, Erovic BM. Merkel cell carcinoma: interdisciplinary management of a rare disease. J Skin Cancer 2013;2013:189342.
Finnigan R, Hruby G, Wratten C et al.. The impact of preradiation residual disease volume on time to locoregional failure in cutaneous Merkel cell carcinoma: a TROG substudy. Int J Radiat Oncol Biol Phys 2013;86:91–95.
Boyer JD, Zitelli JA, Brodland DG, D’Angelo G. Local control of primary Merkel cell carcinoma: review of 45 cases treated with Mohs micrographic surgery with and without adjuvant radiation. J Am Acad Dermatol 2002;47:885–892.
O’Connor WJ, Roenigk RK, Brodland DG. Merkel cell carcinoma: comparison of Mohs micrographic surgery and wide excision in eighty-six patients. Dermatol Surg 1997;23:929–933.
Pennington BE, Leffell DJ. Mohs micrographic surgery: established uses and emerging trends. Oncology (Williston Park) 2005;19:1165–1171; discussion 1171-1172, 1175.
Gupta SG, Wang LC, Penas PF et al.. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: the Dana-Farber experience and meta-analysis of the literature. Arch Dermatol 2006;142:685–690.
Santamaria-Barria JA, Boland GM, Yeap BY et al.. Merkel cell carcinoma: 30-year experience from a single institution. Ann Surg Oncol 2013;20:1365–1373.
Willis AI, Ridge JA. Discordant lymphatic drainage patterns revealed by serial lymphoscintigraphy in cutaneous head and neck malignancies. Head Neck 2007;29:979–985.
Allen PJ, Busam K, Hill AD et al.. Immunohistochemical analysis of sentinel lymph nodes from patients with Merkel cell carcinoma. Cancer 2001;92:1650–1655.
Su LD, Lowe L, Bradford CR et al.. Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in sentinel lymph nodes. J Am Acad Dermatol 2002;46:661–666.
Schmalbach CE, Lowe L, Teknos TN et al.. Reliability of sentinel lymph node biopsy for regional staging of head and neck Merkel cell carcinoma. Arch Otolaryngol Head Neck Surg 2005;131:610–614.
Rush Z, Fields RC, Lee N, Brownell I. Radiation therapy in the management of Merkel cell carcinoma: current perspectives. Expert Rev Dermatol 2011;6:395–404.
Lewis KG, Weinstock MA, Weaver AL, Otley CC. Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol 2006;142:693–700.
Jouary T, Leyral C, Dreno B et al.. Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. Ann Oncol 2012;23:1074–1080.
Mojica P, Smith D, Ellenhorn JD. Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol 2007;25:1043–1047.
Desch L, Kunstfeld R. Merkel cell carcinoma: chemotherapy and emerging new therapeutic options. J Skin Cancer 2013;2013:327150.
Garneski KM, Nghiem P. Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. J Am Acad Dermatol 2007;57:166–169.
Poulsen MG, Rischin D, Porter I et al.. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? Int J Radiat Oncol Biol Phys 2006;64:114–119.
Poulsen M, Rischin D, Walpole E et al.. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study-TROG 96:07. J Clin Oncol 2003;21:4371–4376.
Tai PT, Yu E, Winquist E et al.. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 2000;18:2493–2499.
Voog E, Biron P, Martin JP, Blay JY. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 1999;85:2589–2595.
Pectasides D, Pectasides M, Psyrri A et al.. Cisplatin-based chemotherapy for merkel cell carcinoma of the skin. Cancer Invest 2006;24:780–785.
Paulson KG, Iyer JG, Blom A et al.. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol 2013;133:642–646.